The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients’ survival and long COVID
Maddalena Noviello(San Raffaele University of Rome), Chiara Bonini(Vita-Salute San Raffaele University), Silvia Ghezzi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Valeria Beretta(Vita-Salute San Raffaele University), Norma Maugeri(Vita-Salute San Raffaele University), Gabriel Siracusano(Vita-Salute San Raffaele University), Rebecca De Lorenzo(Vita-Salute San Raffaele University), Eliana Ruggiero(Vita-Salute San Raffaele University), Nicola Ivan Lorè(Istituti di Ricovero e Cura a Carattere Scientifico), Gabriella Scarlatti(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Cugnata(Vita-Salute San Raffaele University), Francesca Sironi(Istituti di Ricovero e Cura a Carattere Scientifico), Fabio Saliu(Istituti di Ricovero e Cura a Carattere Scientifico), Paola M. V. Rancoita(Vita-Salute San Raffaele University), Fabio Ciceri(IRCCS Ospedale San Raffaele), Angelo A. Manfredi(Vita-Salute San Raffaele University), Mauro Malnati, Raniero Chimienti(Istituti di Ricovero e Cura a Carattere Scientifico), Vito Lampasona(IRCCS Ospedale San Raffaele), Aurora Merolla(Vita-Salute San Raffaele University), Elisa Vicenzi(Mario Negri Institute for Pharmacological Research), Elisa Cantarelli(IRCCS Ospedale San Raffaele), Danilo Abbati(Vita-Salute San Raffaele University), Francesco Manfredi(University of Zurich), Cristina Tresoldi(Vita-Salute San Raffaele University), Elena Tassi(University of Milan), Ilaria Marzinotto(IRCCS Ospedale San Raffaele), Paolo Dellabona(Immungenetics (Germany)), Claudia Pastori(Vita-Salute San Raffaele University), Claudia de Lalla(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Cinque(University of California San Diego), Patrizia Rovere‐Querini(Vita-Salute San Raffaele University), Roberta Caccia(Vita-Salute San Raffaele University), Stefania Dispinseri(IRCCS Ospedale San Raffaele), Clelia Di Serio(Vita-Salute San Raffaele University), Lucia Lopalco(Vita-Salute San Raffaele University)
Cited by 12
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Guidelines for the use of flow cytometry and cell sorting in immunological studies <sup>*</sup>
|European Journal of Immunology|2017|554
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Classification of HHV-6A and HHV-6B as distinct viruses
|Archives of Virology|2013|360